Newer IMiDs



With the advent of thalidomide, the treatment of multiple myeloma was revolutionized. The drug showed excellent response rates in both previously untreated and relapsed/refractory patients. However, treatment-related toxicities such as somnolence, constipation, and neuropathy were a major limitation to its use. Lenalidomide, a thalidomide analogue, was developed with the hope of improving both the efficacy and toxicity profile of thalidomide and has subsequently shown significant clinical activity in patients with multiple myeloma. Though approved only for relapsed/refractory patients till date, clinical trials using lenalidomide with or without combinations have shown great efficacy in newly diagnosed, as a maintenance therapy and even asymptomatic myeloma. The recent introduction of another thalidomide analogue-pomalidomide has shown significant activity and a great potential for use in relapsed/refractory myeloma including those refractory to lenalidomide and bortezomib.


Natural Killer Cell Multiple Myeloma Bone Marrow Stromal Cell Natural Killer Cell Cytotoxicity Natural Killer Cell Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Muller GW, Chen R, Huang SY et al (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9(11):1625–1630PubMedCrossRefGoogle Scholar
  2. 2.
    Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520PubMedCrossRefGoogle Scholar
  3. 3.
    Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386PubMedGoogle Scholar
  4. 4.
    Lichtenstein A, Tu Y, Fady C et al (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162(2):248–255PubMedCrossRefGoogle Scholar
  5. 5.
    Breitkreutz I, Raab MS, Vallet S et al (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22(10):1925–1932PubMedCrossRefGoogle Scholar
  6. 6.
    Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31(2–3):213–221PubMedCrossRefGoogle Scholar
  7. 7.
    Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9):3063–3067PubMedCrossRefGoogle Scholar
  8. 8.
    Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39(7–8):1489–1499PubMedCrossRefGoogle Scholar
  9. 9.
    Sharpe AH, Abbas AK (2006) T-cell costimulation–biology, therapeutic potential, and challenges. N Engl J Med 355(10):973–975PubMedCrossRefGoogle Scholar
  10. 10.
    Dredge K, Marriott JB, Todryk SM et al (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168(10):4914–4919PubMedGoogle Scholar
  11. 11.
    Stirling D (2001) Thalidomide: a novel template for anticancer drugs. Semin Oncol 28(6):602–606PubMedCrossRefGoogle Scholar
  12. 12.
    Hayashi T, Hideshima T, Akiyama M et al (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128(2):192–203PubMedCrossRefGoogle Scholar
  13. 13.
    D’Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91(9):4082–4085PubMedCrossRefGoogle Scholar
  14. 14.
    Dredge K, Marriott JB, Macdonald CD et al (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87(10):1166–1172PubMedCrossRefGoogle Scholar
  15. 15.
    Shadduck RK, Latsko JM, Rossetti JM et al (2007) Recent advances in myelodysplastic syndromes. Exp Hematol 35(4 Suppl 1):137–143PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950–1961PubMedCrossRefGoogle Scholar
  17. 17.
    Teo SK (2005) Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7(1):E14–E19PubMedCrossRefGoogle Scholar
  18. 18.
    Dredge K, Horsfall R, Robinson SP et al (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1–2):56–63PubMedCrossRefGoogle Scholar
  19. 19.
    Gandhi AK, Kang J, Naziruddin S et al (2006) Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30(7):849–858PubMedCrossRefGoogle Scholar
  20. 20.
    Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4(4):314–322PubMedCrossRefGoogle Scholar
  21. 21.
    Verhelle D, Corral LG, Wong K et al (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 67(2):746–755PubMedCrossRefGoogle Scholar
  22. 22.
    Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96(9):2943–2950PubMedGoogle Scholar
  23. 23.
    Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12):4525–4530PubMedCrossRefGoogle Scholar
  24. 24.
    Mitsiades CS, Mitsiades NS, Richardson PG et al (2007) Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 101(4):950–968PubMedCrossRefGoogle Scholar
  25. 25.
    RevAssist® for Prescribers. Accessed april 2010 (2010)
  26. 26.
    Dimopoulos MA, Chen C, Spencer A et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11):2147–2152PubMedCrossRefGoogle Scholar
  27. 27.
    Chen C, Reece DE, Siegel D et al (2009) Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 146(2):164–170PubMedCrossRefGoogle Scholar
  28. 28.
    Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108(10):3458–3464PubMedCrossRefGoogle Scholar
  29. 29.
    Richardson P, Jagannath S, Hussein M et al (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114(4):772–778PubMedCrossRefGoogle Scholar
  30. 30.
    Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133–2142PubMedCrossRefGoogle Scholar
  31. 31.
    Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123–2132PubMedCrossRefGoogle Scholar
  32. 32.
    Richardson PG, Weller E, Lonial S et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679–686PubMedCrossRefGoogle Scholar
  33. 33.
    Richardson PG, Siegel D, Baz R et al (2010a) A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. ASH Annual Meeting Abstracts 116(21):864Google Scholar
  34. 34.
    Dimopoulos MA, Kastritis E, Christoulas D et al (2010) Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24(10):1769–1778PubMedCrossRefGoogle Scholar
  35. 35.
    Zonder JA, Crowley J, Hussein MA et al (2010) Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 116(26):5838–5841PubMedCrossRefGoogle Scholar
  36. 36.
    Rajkumar SV, Jacobus S, Callander NS et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29–37PubMedCrossRefGoogle Scholar
  37. 37.
    Gay F, Hayman SR, Lacy MQ et al (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115(7):1343–1350PubMedCrossRefGoogle Scholar
  38. 38.
    Palumbo A, Falco P, Corradini P et al (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian multiple myeloma network. J Clin Oncol 25(28):4459–4465PubMedCrossRefGoogle Scholar
  39. 39.
    Lonial S, Baz R, Swern AS et al (2009) Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. ASH Annual Meeting Abstracts 114(22):2879-Google Scholar
  40. 40.
    Ishak J, Dimopoulos MA, Weber D et al (2008) Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. ASH Annual Meeting Abstracts 112(11):3708-Google Scholar
  41. 41.
    Rajkumar SV, Blood E (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079–2080PubMedCrossRefGoogle Scholar
  42. 42.
    Zonder JA (2006) Thrombotic complications of myeloma therapy. Hematology 2006(1):348–355CrossRefGoogle Scholar
  43. 43.
    Cavallo F, Raimondo FD, Harda I et al (2010) A phase III study of enoxaparin vs aspirin as thromboprophylaxis for newly diagnosed myeloma patients treated with lenalidomide-based regimen. ASH Annual Meeting Abstracts 116(21):1092-Google Scholar
  44. 44.
    Klein U, Kosely F, Hillengass J et al (2009) Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 88(1):67–71PubMedCrossRefGoogle Scholar
  45. 45.
    Kneppers E, Lokhorst HM, Eeltink CM et al (2010) Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 10(2):138–143PubMedCrossRefGoogle Scholar
  46. 46.
    Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423PubMedCrossRefGoogle Scholar
  47. 47.
    Menon SP, Rajkumar SV, Lacy M et al (2008) Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 112(7):1522–1528PubMedCrossRefGoogle Scholar
  48. 48.
    Minnema MC, Breitkreutz I, Auwerda JJ et al (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18(12):2044–2046PubMedCrossRefGoogle Scholar
  49. 49.
    Dimopoulos MA, Palumbo A, Attal M et al (2011) Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 25(5):749–760PubMedCrossRefGoogle Scholar
  50. 50.
    Delforge M, Facon T, Bravo M-L et al (2009) Lenalidomide plus dexamethasone has similar tolerability and efficacy in treatment of relapsed/refractory multiple myeloma patients with or without history of neuropathy. ASH Annual Meeting Abstracts 114(22):3873-Google Scholar
  51. 51.
    Sviggum HP, Davis MD, Rajkumar SV et al (2006) Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 142(10):1298–1302PubMedCrossRefGoogle Scholar
  52. 52.
    Darabi K, Kantamnei S, Wiernik PH (2006) Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol 24(35):e59PubMedCrossRefGoogle Scholar
  53. 53.
    Harousseau JL, Dimopoulos MA, Wang M et al (2010) Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95(10):1738–1744PubMedCrossRefGoogle Scholar
  54. 54.
    San-Miguel JF, Dimopoulos MA, Stadtmauer EA, et al (2011) Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 11(1):38–43Google Scholar
  55. 55.
    Reece D, Song KW, Fu T et al (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114(3):522–525PubMedCrossRefGoogle Scholar
  56. 56.
    Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25(25):3892–3901PubMedCrossRefGoogle Scholar
  57. 57.
    Anderson KC, Jagannath S, Jakubowiak A et al (2009) Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. ASCO Meeting Abstracts 27(15S):8536Google Scholar
  58. 58.
    Richardson P, Jagannath S, Jakubowiak A et al (2008) Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. ASH Annual Meeting Abstracts 112(11):1742.Google Scholar
  59. 59.
    Zonder JA, Barlogie B, Durie BGM et al (2006) Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108(1):403–404PubMedCrossRefGoogle Scholar
  60. 60.
    Baz R, Patel M, Finley-Oliver E et al (2010) Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma 51(6):1015–1019PubMedCrossRefGoogle Scholar
  61. 61.
    Palumbo A, Falco P, Benevolo G et al (2010) A multicenter, open label study of oral lenalidomide and prednisone (RP) followed by oral lenalidomide melphalan and prednisone (MPR) and oral lenalidomide maintenance in newly diagnosed elderly multiple myeloma patients. ASH Annual Meeting Abstracts 116(21):1940Google Scholar
  62. 62.
    Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289–3294PubMedCrossRefGoogle Scholar
  63. 63.
    Barlogie B, Pineda-Roman M, van Rhee F et al (2008) Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112(8):3115–3121PubMedCrossRefGoogle Scholar
  64. 64.
    Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354(10):1021–1030PubMedCrossRefGoogle Scholar
  65. 65.
    Spencer A, Prince HM, Roberts AW et al (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27(11):1788–1793PubMedCrossRefGoogle Scholar
  66. 66.
    McCarthy PL, Owzar K, Anderson KC et al (2010) Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. ASCO Meeting Abstracts 28 (15_suppl):8017Google Scholar
  67. 67.
    Attal M, Cristini C, Marit G et al (2010) Lenalidomide maintenance after transplantation for myeloma. ASCO Meeting Abstracts 28(15_suppl):8018Google Scholar
  68. 68.
    International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749–757CrossRefGoogle Scholar
  69. 69.
    Kyle RA, Remstein ED, Therneau TM et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582–2590PubMedCrossRefGoogle Scholar
  70. 70.
    Barlogie B, van Rhee F, Shaughnessy JD Jr et al (2008) Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112(8):3122–3125PubMedCrossRefGoogle Scholar
  71. 71.
    Rajkumar SV, Gertz MA, Lacy MQ et al (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17(4):775–779PubMedCrossRefGoogle Scholar
  72. 72.
    Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16–19PubMedCrossRefGoogle Scholar
  73. 73.
    Mateos M-V, Lopez-Corral L, Hernandez MT et al. (2009) Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic mm: results of the first interim analysis. ASH Annual Meeting Abstracts 114(22):614Google Scholar
  74. 74.
    Galustian C, Meyer B, Labarthe MC et al (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58(7):1033–1045PubMedCrossRefGoogle Scholar
  75. 75.
    Schey SA, Fields P, Bartlett JB et al (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22(16):3269–3276PubMedCrossRefGoogle Scholar
  76. 76.
    Anderson G, Gries M, Kurihara N et al (2006) Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107(8):3098–3105PubMedCrossRefGoogle Scholar
  77. 77.
    Ferguson GD, Jensen-Pergakes K, Wilkey C et al (2007) Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 27(2):210–220PubMedCrossRefGoogle Scholar
  78. 78.
    Streetly MJ, Gyertson K, Daniel Y et al (2008) Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 141(1):41–51PubMedCrossRefGoogle Scholar
  79. 79.
    Lacy MQ, Hayman SR, Gertz MA et al (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27(30):5008–5014PubMedCrossRefGoogle Scholar
  80. 80.
    Lacy MQ, Hayman SR, Gertz MA et al (2010) Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24(11):1934–1939PubMedCrossRefGoogle Scholar
  81. 81.
    Lacy M, Mandrekar S, Gertz MAA et al (2010a) Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. ASH Annual Meeting Abstracts 116(21):863-Google Scholar
  82. 82.
    Leleu X, Attal M, Moreau P et al (2010) Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009–02. ASH Annual Meeting Abstracts 116(21):859-Google Scholar
  83. 83.
    Begna KH, Mesa RA, Pardanani A et al (2011) A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25(2):301–304PubMedCrossRefGoogle Scholar
  84. 84.
    Streetly M, Stewart O, Gyertson K et al (2009) Pomalidomide monotherapy for relapsed myeloma is associated with excellent responses and prolonged progression free and overall survival. ASH Annual Meeting Abstracts 114(22):3878Google Scholar
  85. 85.
    Short KD, Rajkumar SV, Larson D et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25(6):906–908PubMedCrossRefGoogle Scholar
  86. 86.
    Baz R, Walker E, Karam MA, et al (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 17(12):1766–1771PubMedCrossRefGoogle Scholar
  87. 87.
    Knop S, Gerecke C, Liebisch P, et al (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113(18):4137–4143PubMedCrossRefGoogle Scholar
  88. 88.
    Morgan GJ, Schey SA, Wu P, et al (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137(13):268–269PubMedCrossRefGoogle Scholar
  89. 89.
    Schey SA, Morgan GJ, Ramasamy K, et al (2010) The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology 150(3):326–333PubMedCrossRefGoogle Scholar
  90. 90.
    Reece DE, Masih-Khan E, Khan A, et al (2010) Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid(R)) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma. ASH Annual Meeting Abstracts 116:3055PubMedCrossRefGoogle Scholar
  91. 91.
    Lacy MQ, Gertz MA, Dispenzieri A, et al (2007) Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clinic Proceedings 82(10):1179–1184PubMedCrossRefGoogle Scholar
  92. 92.
    Niesvizky R, Jayabalan DS, Christos PJ, et al (2008) BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111(3):1101–1109PubMedCrossRefGoogle Scholar
  93. 93.
    Kumar SK, Flinn I, Noga SJ, et al (2010) Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia 24(7):1350–1356PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.The Division of HematologyMayo ClinicRochesterUSA

Personalised recommendations